Monty Pal and Jaime Landman discuss the value of collaboration with multiple disciplines to effectively manage patients diagnosed with kidney cancer. They provide a historical overview of the treatment of kidney cancer bringing the conversation to revolutionary advances, adding their view on the impact of survival in this patient population.

In this episode of Kidney Cancer Today, Bradley McGregor joins Monty Pal and Jamie Landman to speak about the major practice-changing studies that have come out over the past year in the frontline setting and the evolution of therapy in the renal cell carcinoma space.  

Biopsy or not to biopsy...that is the question in this debate between Jaime Landman and Michael Staehler hosted by Monty Pal.  Do we biopsy the small renal mass patient or do we diagnose the patient using exclusively imaging?  The case is made by Jaime to consider why this is the only cancer we do not routinely biopsy.  They discuss why the approach in small renal masses is unique.

 

Monty Pal and Jaime Landman discuss the value of collaboration with multiple disciplines to effectively manage patients diagnosed with kidney cancer. They provide a historical overview of the treatment of kidney cancer bringing the conversation to revolutionary advances, adding their view on the impact of survival in this patient population.